Beyond breast and gastric cancer, HER2 overexpression has been described in other solid tumors, including biliary tract cancer, colorectal cancer, pancreatic cancer, and ovarian cancer, among others3, but HER2 therapies have yet to have achieved approval in those cancers. Here, ERBB2 is linked to cancer.